{"id":"alemtuzumab-gz402673","safety":{"commonSideEffects":[{"rate":"70–90","effect":"Infusion reactions"},{"rate":"high","effect":"Lymphopenia"},{"rate":"30–50","effect":"Infections"},{"rate":"5–10","effect":"Autoimmune thyroid disease"},{"rate":"1–5","effect":"Immune thrombocytopenia"},{"rate":"20–30","effect":"Headache"},{"rate":"15–25","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alemtuzumab targets CD52, a cell surface antigen present on B cells, T cells, and other lymphocytes. Upon binding, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), resulting in rapid lymphocyte depletion. This immunosuppressive effect reduces autoreactive lymphocytes and is used therapeutically in autoimmune and hematologic conditions.","oneSentence":"Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:46.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT03774914","phase":"","title":"LEMTRADA Pregnancy Registry in Multiple Sclerosis","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-09-01","conditions":"Multiple Sclerosis","enrollment":42},{"nctId":"NCT02255656","phase":"PHASE4","title":"Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-01-07","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":1062},{"nctId":"NCT02583594","phase":"PHASE1","title":"A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-12-06","conditions":"Progressive Multiple Sclerosis","enrollment":24},{"nctId":"NCT02205489","phase":"PHASE4","title":"Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lemtrada"],"phase":"marketed","status":"active","brandName":"Alemtuzumab (GZ402673)","genericName":"Alemtuzumab (GZ402673)","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion. Used for Relapsing-remitting multiple sclerosis, Chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}